graph EGM comparisons
pembrolizumab alonetitleatezolizumab alonetitlenivolumab alonetitlecemiplimabtitledurvalumab alonetitleStandard of Care (SoC)titleIMpower-110 (TC3 or IC3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 107/98IMpower-110 (TC2/3 or IC2/3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 166/162IMpower-110 (TC1/2/3 or IC1/2/3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 277/277EMPOWER lung1 (PDL1>50%), 2021 NCT03088540 mNSCLC - L1 - PDL1 positive 283/280MYSTIC (D ; PDL1>25%), 2020 NCT02453282 mNSCLC - L1 - PDL1 positive 163/162CheckMate 026 (PDL1>1%), 2016 NCT02041533 mNSCLC - L1 - PDL1 positive 271/270CheckMate 026 (PDL1>5%), 2016 NCT02041533 mNSCLC - L1 - PDL1 positive 211/212KEYNOTE-042 (PDL1>20%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 413/405KEYNOTE-042 (PDL1>1%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 637/637KEYNOTE-024 (PDL1>50%), 2016 NCT02142738 mNSCLC - L1 - PDL1 positive 154/151KEYNOTE-042 (PDL1>50%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 299/300

Pathology:  mNSCLC - L1 - PDL1 positive; 

mNSCLC - L1 - PDL1 positive
IMpower-110 (TC3 or IC3), 2020IMpower-110 (TC2/3 or IC2/3), 2020IMpower-110 (TC1/2/3 or IC1/2/3), 2020EMPOWER lung1 (PDL1>50%), 2021MYSTIC (D ; PDL1>25%), 2020CheckMate 026 (PDL1>1%), 2016CheckMate 026 (PDL1>5%), 2016KEYNOTE-042 (PDL1>20%), 2019KEYNOTE-042 (PDL1>1%), 2019KEYNOTE-024 (PDL1>50%), 2016KEYNOTE-042 (PDL1>50%), 2019
pembrolizumab alone4T1T1T1T1
atezolizumab alone3T1T1T1
nivolumab alone2T1T1
cemiplimab1T1
durvalumab alone1T1
Standard of Care (SoC)0T0T0T0T0T0T0T0T0T0T0T0